Procoagulant platelets: Laboratory detection and clinical significance.

Tytuł:: Procoagulant platelets: Laboratory detection and clinical significance.
Autorzy:: Tohidi-Esfahani I; ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.; Department of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
Lee CSM; ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Liang HPH; ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Chen VMY; ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.; Department of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
Źródło:: International journal of laboratory hematology [Int J Lab Hematol] 2020 Jun; Vol. 42 Suppl 1, pp. 59-67.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Oxford : Blackwell Scientific Publications, c2007-
MeSH Terms:: Algorithms*
Blood Coagulation Disorders*/blood
Blood Coagulation Disorders*/diagnosis
Blood Coagulation Disorders*/therapy
Blood Platelets*/metabolism
Blood Platelets*/pathology
Hemophilia A*/blood
Hemophilia A*/diagnosis
Hemophilia A*/therapy
Platelet Activation*
Thrombosis*/blood
Thrombosis*/diagnosis
Thrombosis*/therapy
Humans
References:: Organization WH.Cardiovascular diseases (CVDs). https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Published 2017. Updated 17th May 2017. Accessed 3rd February, 2020.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost. 2013;11(1):2-16.
Lesyk G, Jurasz P. Advances in platelet subpopulation research. Front Cardiovasc Med. 2019;6:138.
Fager AM, Wood JP, Bouchard BA, Feng P, Tracy PB. Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. Arterioscler Thromb Vasc Biol. 2010;30(12):2400-2407.
Sodergren AL, Ramstrom S. Platelet subpopulations remain despite strong dual agonist stimulation and can be characterised using a novel six-colour flow cytometry protocol. Sci Rep. 2018;8(1):1441.
Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982;122(2):429-436.
Schick PK, Kurica KB, Chacko GK. Location of phosphatidylethanolamine and phosphatidylserine in the human platelet plasma membrane. J Clin Invest. 1976;57(5):1221-1226.
Lhermusier T, Chap H, Payrastre B. Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. J Thromb Haemost. 2011;9(10):1883-1891.
Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature. 2010;468(7325):834-838.
van Kruchten R, Mattheij NJA, Saunders C, et al. Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood. 2013;121(10):1850-1857.
Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood. 1997;90(7):2615-2625.
Panteleev MA, Ananyeva NM, Greco NJ, Ataullakhanov FI, Saenko EL. Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex. J Thromb Haemost. 2005;3(11):2545-2553.
Berny MA, Munnix ICA, Auger JM, et al. Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One. 2010;5(4):e10415.
Swieringa F, Kuijpers MJ, Lamers MM, van der Meijden PE, Heemskerk JW. Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow. Haematologica. 2015;100(6):748-756.
Agbani EO, Poole AW. Procoagulant platelets: generation, function, and therapeutic targeting in thrombosis. Blood. 2017;130(20):2171-2179.
Agbani EO, van den Bosch MTJ, Brown ED, et al. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation. 2015;132(15):1414-1424.
Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009;114(3):663-666.
Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118(6):1663-1674.
Choo HJ, Kholmukhamedov A, Zhou C, Jobe S. Inner mitochondrial membrane disruption links apoptotic and agonist-initiated phosphatidylserine externalization in platelets. Arterioscler Thromb Vasc Biol. 2017;37(8):1503-1512.
Jobe SM, Wilson KM, Leo L, et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111(3):1257-1265.
Denorme F, Manne BK, Portier I, et al. Platelet necrosis mediates ischemic stroke outcome in mice. Blood. 2019.
Hua VM, Abeynaike L, Glaros E, et al. Necrotic platelets provide a procoagulant surface during thrombosis. Blood. 2015;126(26):2852-2862.
Shi J, Pipe SW, Rasmussen JT, Heegaard CW, Gilbert GE. Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure. J Thromb Haemost. 2008;6(7):1167-1174.
Pasalic L, Wing-Lun E, Lau JK, et al. Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. J Thromb Haemost. 2018;16(6):1198-1210.
Tan CW, Bourcy M, Pasalic L, Chen VM. Flow cytometry assessment of procoagulant platelets using a dithiol-reactive probe. In: Hogg PJ, ed. Functional Disulphide Bonds: Methods and Protocols, 1st edn. Clifton, NJ. Humana Press; 2019:305-321.
Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415(6868):175-179.
Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3(10):2185-2192.
Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95(5):1694-1702.
Hamilton SF, Miller MW, Thompson CA, Dale GL. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro. J Lab Clin Med. 2004;143(5):320-326.
Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets are higher in amnestic versus nonamnestic patients with mild cognitive impairment. Alzheimer Dis Assoc Disord. 2007;21(3):259-261.
Munnix ICA, Kuijpers MJE, Auger J, et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol. 2007;27(11):2484-2490.
Podoplelova NA, Sveshnikova AN, Kotova YN, et al. Coagulation factors bound to procoagulant platelets concentrate in cap structures to promote clotting. Blood. 2016;128(13):1745-1755.
Agbani EO, Hers I, Poole AW. Temporal contribution of the platelet body and balloon to thrombin generation. Haematologica. 2017;102(10):e379-e381.
Obydennyy SI, Sveshnikova AN, Ataullakhanov FI, Panteleev MA. Dynamics of calcium spiking, mitochondrial collapse and phosphatidylserine exposure in platelet subpopulations during activation. J Thromb Haemost. 2016;14(9):1867-1881.
Kholmukhamedov A, Janecke R, Choo HJ, Jobe SM. The mitochondrial calcium uniporter regulates procoagulant platelet formation. J Thromb Haemost. 2018;16(11):2315-2321.
Wang L, Bi Y, Cao M, et al. Microparticles and blood cells induce procoagulant activity via phosphatidylserine exposure in NSTEMI patients following stent implantation. Int J Cardiol. 2016;223:121-128.
Kirkpatrick AC, Vincent AS, Dale GL, Prodan CI. Increased platelet procoagulant potential predicts recurrent stroke and TIA after lacunar infarction. J Thromb Haemost. 2020;18(3):660-668.
Zhao L, Bi Y, Kou J, Shi J, Piao D. Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients. J Exp Clin Cancer Res. 2016;35:54.
Vulliamy P, Gillespie S, Armstrong PC, Allan HE, Warner TD, Brohi K. Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. Proc Natl Acad Sci U S A. 2019;116(35):17444-17449.
Guo LI, Tong D, Yu M, et al. Phosphatidylserine-exposing cells contribute to the hypercoagulable state in patients with multiple myeloma. Int J Oncol. 2018;52(6):1981-1990.
Panova-Noeva M, Marchetti M, Spronk HM, et al. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol. 2011;86(4):337-342.
Tong D, Yu M, Guo LI, et al. Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients. Ann Hematol. 2018;97(4):605-616.
Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood. 1996;87(4):1409-1415.
Rabbolini D, Connor D, Morel-Kopp M-C, et al. An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. Pathology. 2020;52(2):243-255.
Saxena K, Pethe K, Dale GL. Coated-platelet levels may explain some variability in clinical phenotypes observed with severe hemophilia. J Thromb Haemost. 2010;8(5):1140-1142.
Handtke S, Steil L, Greinacher A, Thiele T. Toward the relevance of platelet subpopulations for transfusion medicine. Front Med (Lausanne). 2018;5:17-17.
Dasgupta SK, Argaiz ER, Mercado JEC, et al. Platelet senescence and phosphatidylserine exposure. Transfusion. 2010;50(10):2167-2175.
Ma R, Xie R, Yu C, et al. Phosphatidylserine-mediated platelet clearance by endothelium decreases platelet aggregates and procoagulant activity in sepsis. Sci Rep. 2017;7(1):4978-4978.
Agbani EO, Williams CM, Li Y, et al. Aquaporin-1 regulates platelet procoagulant membrane dynamics and in vivo thrombosis. JCI Insight. 2018;3(10):e99062.
Agbani EO, Zhao X, Williams CM, et al. Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis. Platelets. 2020;1:1-7. https://doi.org/10.1080/09537104.2019.
Zhang J, An YU, Gao J, et al. Aquaporin-1 translocation and degradation mediates the water transportation mechanism of acetazolamide. PLoS One. 2012;7(9):e45976.
Tullemans BME, Nagy M, Sabrkhany S, et al. Tyrosine kinase inhibitor pazopanib inhibits platelet procoagulant activity in renal cell carcinoma patients. Front Cardiovasc Med. 2018;5:142-142.
Siljander P, Farndale RW, Feijge MAH, et al. Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol. 2001;21(4):618-627.
Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102(2):449-461.
Andre P, McKenzie SE, Bergmeier W. The parallel signaling pathways of phosphatidylserine (PS) exposure downstream of platelet FcγRIIa. Blood. 2013;122(21):3514-3514.
Kourtzelis I, Kotlabova K, Lim J-H, et al. Developmental endothelial locus-1 modulates platelet-monocyte interactions and instant blood-mediated inflammatory reaction in islet transplantation. Thromb Haemost. 2016;115(4):781-788.
Reilly MP, Sinha U, André P, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 2011;117(7):2241-2246.
Kogan I, Chap D, Hoffman R, Axelman E, Brenner B, Nadir Y. JAK-2 V617F mutation increases heparanase procoagulant activity. Thromb Haemost. 2016;115(1):73-80.
Crispel Y, Ghanem S, Attias J, Kogan I, Brenner B, Nadir Y. Involvement of the heparanase procoagulant domain in bleeding and wound healing. J Thromb Haemost. 2017;15(7):1463-1472.
Grant Information:: New South Wales, Ministry of Health Cardiovascular Capacity Building Grants, Australia
Contributed Indexing:: Keywords: haemostasis; platelet function; platelets; procoagulant activity; thrombosis
SCR Disease Name:: Scott Syndrome
Entry Date(s):: Date Created: 20200617 Date Completed: 20210105 Latest Revision: 20210105
Update Code:: 20240105
DOI:: 10.1111/ijlh.13197
PMID:: 32543068
: Czasopismo naukowe

Pełny tekst

Platelets play a critical role in both haemostasis and thrombosis, and it is now evident that not all platelets behave the same when they are called to action. A functionally distinct subpopulation of platelets forms in response to maximal agonist stimulation: the procoagulant platelet. This platelet subpopulation is defined by its ability to expose phosphatidylserine on its surface, allowing for coagulation factor complexes to form and generate bursts of thrombin and fibrin to stabilize platelet clots. Reduced levels of procoagulant platelets have been linked to bleeding in Scott's syndrome and haemophilia A patients, and elevated levels have been demonstrated in many thrombotic disorders, including identifying patients at higher risk for stroke recurrence. One obstacle for incorporating an assay for measuring procoagulant platelets into clinical management algorithms is the lack of consensus on the exact definition and markers for this subpopulation. This review will outline the biological characteristics of procoagulant platelets and the laboratory assays currently used to identify them in research settings. It will summarize the findings of clinical research demonstrating the relevance of measuring the procoagulant platelet levels in patients and will discuss how an appropriate assay can be used to elucidate the mechanism behind the formation of this subpopulation, facilitating novel drug discovery to improve upon current outcomes in cardiovascular and other thrombotic disorders.
(© 2020 John Wiley & Sons Ltd.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja